Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing. Sofinnova Partners and Lightstone Ventures led the round.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: